



Dr Marie-Caroline TRONE

Hospital-based Ophthalmologist
Saint-Étienne University Hospital – France

Key words

Dry eye syndrome (DES) – Meibomian gland dysfunction (MGD)
Dry eye – Ocular surface – LacryDiag® – Tear film – OSDI – BUT
NIBUT - Meibography - Interferometry – Intense pulsed light (IPL)
C.Stim® – TFOS-DEW II

Summary

Diagnosis and treatment of a female patient with evaporative **Dry Eye Syndrome (DES)** and **moderate Meibomian Gland Dysfunction (MGD)** aggravated by working at a screen and wearing a mask. A full diagnosis was performed by means of clinical examination and **LacryDiag®** examinations. **C.Stim® intense pulsed light treatment** was initiated in this patient. After three months, **a significant reduction in symptoms was observed, with an improvement in the patient’s MGD from moderate to mild.**

1

Clinical examination

2

LacryDiag® examination

3

Initial care

4


IPL treatment
C.Stim®

5

Results at three months

Patient history


- 49-year-old woman
- Executive assistant, works at a screen 7–8 hours per day
- Visual discomfort with red, itchy, gritty eyes, especially in the morning upon waking and at the end of the day
- Increased sensitivity to light, both on screen and outdoors



- Symptoms have become worse over recent months and are aggravated by wearing a mask

Clinical examination

- Interview:**
- No relevant medical history
 - Not on any medication
 - Identification of DES risk factors:
=> Active smoker (approx. 10 cigarettes/day)
 - OSDI = 43.75



Focus on the use of questionnaires

There are numerous questionnaires, but the most commonly used are: OSDI, DEQ-5, SPEED.

Benefits:


- Useful supplement to the interview
- Rapid assessment of the severity and variety of symptoms experienced
- Can be used to monitor DES progression and the effects of any treatments given
- Simple: can be filled in by patients in the waiting room

Eye examination:


OD		OS	
10/10 Pa 2 +0,75 add+0,75	AV	10/10 Pa2 +1,00 add+0,75	
16 mmHg	PIO	17 mmHg	

Slit lamp examination:

- Moderate MGD
- Incomplete blinking
- OD BUT 5 seconds
- OS BUT 4 seconds with significant tear instability



Telangiectasia along the free margin, meibum thick and difficult to express, several meibomian glands blocked



A few spots of superficial punctate keratitis on the lower eye

LacryDiag[®] examination

Interferometry: disrupted => Disruption of the lipid layer

Tear meniscus height: normal

NIBUT: decreased to 5.6 seconds => Tear instability

Meibography:

- A few dilated and blocked meibomian glands
- Several glands atrophied




Focus on the diagnosis

Moderate Meibomian Gland Dysfunction (MGD) causing evaporative Dry Eye Syndrome (DES).

For a better treatment compliance:

Patient information and explanation of the physiopathology (personalised information sheet and website: www.mydryeyedisease.com)



3

Initial care

- Instillation of preservative-free artificial tears multiple times daily
- Eyelid care (*heating, massage, cleaning*)
- Blinking exercises
- Encouragement to stop smoking!
(*Explanation of the harmful role of smoke, particularly on the ocular surface*)




Two-month check-up

- Patient still experiencing discomfort
- Symptoms reduced but still present, despite good treatment compliance
- Moderate MGD upon clinical examination

▶ C.Stim® IPL treatment initiated

▶ Symptomatic treatment continued



4

C.Stim® IPL treatment

- Treatment protocol: three sessions on D0, D15 and D45
- 4 shots per side per session at a fluence of 8 to 14 J/cm²
- Protective goggles worn by patient and doctor
- Expression of meibum with forceps after each session to optimise the results



Results at three months

Marked improvement in symptoms: OSDI 43.75 on D0 / OSDI 25 at M3

Improvement in MGD: Moderate before treatment / Mild after treatment

- ▶ Symptomatic treatment will need to continue long term
- ▶ Further IPL treatment as necessary

Conclusion

- IPL treatment with C.Stim® is fast, effective and safe.
- C.Stim® IPL can be offered to patients with MGD when symptomatic treatment is insufficiently effective.

Focus on Meibomian Gland Dysfunction (MGD)

Aetiology of MGD




Fig. 3. Pathophysiology of MGD. Please see the original report for a complete description of this figure [7].

Classification of MGD

0




Pas de perte

1




Perte entre 0 et 25%

2



Perte entre 25 et 50%

3



Perte entre 50 et 75%

4



Perte entre 75 et 100%

Bibliography

1. Parasympathetic Innervation of the Meibomian Glands in Rats - Mark S. LeDoux et al. - Investigative Ophthalmology & Visual Science, October 2001, Vol. 42, No. 11
2. Characterization of the innervation of the meibomian glands in humans, rats and mice - Bründl, M. et al. Annals of Anatomy (2021), Vol. 233.
3. Neurotransmitter Influence on Human Meibomian Gland Epithelial Cells - Wendy R. Kam and David A. Sullivan - Investigative Ophthalmology & Visual Science, November 2011, Vol. 52, No. 12
4. The Dopaminergic Neuronal System Regulates the Inflammatory Status of Mouse Lacrimal Glands in Dry Eye Disease - Ji, Yong Woo et al. Investigative Ophthalmology & Visual Science (2021), Vol. 62.
5. TFOS DEWS II pathophysiology report - Anthony J. Bron, et al. - The Ocular Surface, 2017, p 441 to 515
6. The neurobiology of the meibomian glands - Cox SM, Nichols JJ - Ocular Surface, July 2014
7. Multicenter Study of Intense Pulsed Light Therapy for Patients with Refractory Meibomian Gland Dysfunction - Reiko Arita, et al. - Cornea Volume 37, Number 12, December 2018
8. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition - Yu Ri Woo, et al. International Journal of Molecular Sciences, September 2016
9. Rosacea: Epidemiology, pathogenesis, and treatment - Barbara M. Rainer et al. - DERMATO-ENDOCRINOLOGY 2018, VOL. 9, NO. 1, e1361574 (10 pages)
10. Treatment of ocular rosacea - Edward Wladis et al. - Survey of Ophthalmology (2018), Vol.63.
11. Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm-wavelength intense pulsed light: A prospective randomized controlled trial with a 2-year follow-up - Luo, Y. et al. - Experimental and Therapeutic Medicine (2020), Vol. 19.
12. Therapeutic Effect of Intense Pulsed Light on Ocular Demodicosis - Zhang, X., et al. - Current Eye Research 2019, Vol. 3.
13. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation - Cheng et al. - Current Medical Sciences (2019), Vol.39.
14. Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction - Seo Kyoung Yul et al. - Contact Lens and Anterior Eye (2018), Vol. 41.
15. TFOS DEWS II Tear Film Report - Willcox Mark et al. - The Ocular Surface (2017), Vol.15.
16. Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction - Vigo, L. et al. - Journal of Visualized Experiment (2019), N° 146.
17. Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines - Choi, M. et al. - Scientific Reports (2019), Vol.9.
18. TFOS DEWS II pain and sensation report - Belmonte Carlos, et al. - The Ocular Surface (2017), Vol.15.
19. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction - LIU, R et al. - American Journal of Ophthalmology (2017).
20. Effect of inflammation on lacrimal gland function - Driss Zoukhri - Experimental Eye Research, May 2006; 82(5): 885-898
21. Aqueous deficiency is a contributor to evaporation-related dry eye disease - Charles W. McMonnies - Eye and Vision (2020) 7:6.

The LacyrDiag® ocular surface analyser is a non-invasive, class I diagnostic medical device, designed and manufactured by SBM Sistemi and distributed by Quantel Medical. The C.Stim® is a class IIb medical device designed and manufactured by Quantel Medical and compliance assessed by LNE/G-MED « CE 0459 ». XS_CLINICAL_CASE_01_LACRYDIAG_CSTIM_220516